Asco Gu 2022 Impact Of Pd L1 Expression On Conventional Urothelial 563 background: immunohistochemistry (ihc) to determine pd l1 expression level has been proposed a companion assay related to the approval of immune checkpoint inhibitors in ubc. we hypothesized that the ga profiles would differ between ubc featuring high vs negative pd l1 expression. methods: 102 cases of advanced ubc with known pd l1 expression underwent hybrid capture based comprehensive. We hypothesized that the ga profiles would differ between ucb featuring high vs negative pd l1 expression. methods: 102 cases of advanced ucb with known pd l1 tumor cell expression underwent hybrid capture based comprehensive genomic profiling to evaluate all classes of genomic alteration (ga). tumor mutational burden (tmb) was determined on up.
Asco Gu 2022 Impact Of Pd L1 Expression On Conventional Urothelial Pd l1 ihc may thus not only play a role in the selection of icpi for advanced ucb but also in designing trials that may combine icpi with targeted therapies. research sponsor: foundation medicine inc. ubc high pd l1 expression (24 cases) ubc negative pd l1 expression (78 cases) p value gloh mean 10.8% 9.0% ns tp53 75.0% 50.6% ns tert 91.7% 77.2% ns. Tumours with high pd l1 expression respond better to anti pd l1 agents and as approved by the fda, these patients may be candidates for ici therapy (figure 16 and and17). 17). pd l1 expression may also be heterogeneous in the same tumor due to several other factors, such as whether the patient was given any chemotherapy previously and the type. The gene expression analysis also reveals up regulations of the immune checkpoints pd l1, pd l2 and pd1 (pd 1: log2fc = 1.67, pd l1: log2fc = 4 and pd l2: log2fc = 2.86) in the analyzed bladder. Request pdf | impact of pd l1 expression on conventional urothelial bladder carcinoma (ubc) genomic alteration (ga) profile. | 563 background: immunohistochemistry (ihc) to determine pd l1.
Comments are closed.